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Research

High-throughput allele-specific expression across 250
environmental conditions
Gregory A. Moyerbrailean,1,4 Allison L. Richards,1,4 Daniel Kurtz,1,4 Cynthia A. Kalita,1,4
Gordon O. Davis,1 Chris T. Harvey,1 Adnan Alazizi,1 Donovan Watza,1 Yoram Sorokin,2
Nancy Hauff,2 Xiang Zhou,3 Xiaoquan Wen,3 Roger Pique-Regi,1,2 and Francesca Luca1,2
1

Center for Molecular Medicine and Genetics, Wayne State University, Detroit, Michigan 48201, USA; 2Department of Obstetrics
and Gynecology, Wayne State University, Detroit, Michigan 48201, USA; 3Department of Biostatistics, University of Michigan,
Ann Arbor, Michigan 48109, USA
Gene-by-environment (GxE) interactions determine common disease risk factors and biomedically relevant complex traits.
However, quantifying how the environment modulates genetic effects on human quantitative phenotypes presents unique
challenges. Environmental covariates are complex and difficult to measure and control at the organismal level, as found in
GWAS and epidemiological studies. An alternative approach focuses on the cellular environment using in vitro treatments
as a proxy for the organismal environment. These cellular environments simplify the organism-level environmental exposures to provide a tractable influence on subcellular phenotypes, such as gene expression. Expression quantitative trait loci
(eQTL) mapping studies identified GxE interactions in response to drug treatment and pathogen exposure. However, eQTL
mapping approaches are infeasible for large-scale analysis of multiple cellular environments. Recently, allele-specific expression (ASE) analysis emerged as a powerful tool to identify GxE interactions in gene expression patterns by exploiting
naturally occurring environmental exposures. Here we characterized genetic effects on the transcriptional response to
50 treatments in five cell types. We discovered 1455 genes with ASE (FDR < 10%) and 215 genes with GxE interactions.
We demonstrated a major role for GxE interactions in complex traits. Genes with a transcriptional response to environmental perturbations showed sevenfold higher odds of being found in GWAS. Additionally, 105 genes that indicated GxE
interactions (49%) were identified by GWAS as associated with complex traits. Examples include GIPR–caffeine interaction
and obesity and include LAMP3–selenium interaction and Parkinson disease. Our results demonstrate that comprehensive
catalogs of GxE interactions are indispensable to thoroughly annotate genes and bridge epidemiological and genomewide association studies.
[Supplemental material is available for this article.]

For complex traits, a mismatch between genotype and environment can cause a higher disease risk. However, it is generally
difficult to determine the relevant environmental factors to measure in order to study gene-by-environment (GxE) interactions.
Consequently, some of the genetic effect sizes measured in
GWAS may be underestimated when the relevant environmental
factors are not controlled. Molecular phenotypes measured in
tightly controlled cellular environments provide a more tractable
setting in which we can study GxE interactions simplifying both
complex phenotypes and environments (Fig. 1A). The cellular
environment is determined by the complex of stimuli (e.g., hormonal and metabolic) to which a cell is exposed, can be defined
as an agent that can potentially change the state of the cell, and
is measurable at the molecular level. Examples include, agents
secreted by nearby cells, hormones and metabolites secreted by
other organs, pollutants, drugs, or micronutrients absorbed by
the organisms. For example, physical or emotional environmental
stressors alter blood glucocorticoid levels, which induce significant cellular changes in global gene expression patterns mediated
through glucocorticoid receptor (GR) activation (Grundberg et al.
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2011; Luca et al. 2013). Response expression quantitative trait
loci (reQTL) mapping studies found that SNPs associated with
specific immune traits are enriched for infection reQTL and for expression quantitative trait loci (eQTL) identified only in infected
cells (Barreiro et al. 2012; Fairfax et al. 2014; Lee et al. 2014).
However, eQTL mapping requires a large number of samples,
thus limiting the number of cellular environments that can be analyzed in parallel. While association mapping compares genotypic
effects across individuals that have different genetic backgrounds,
allele-specific expression (ASE) approaches compare allelic effects
within individuals, thereby controlling for genetic background
and cellular environment. Currently, ASE approaches represent
the most effective assay to quantify cis-regulatory variants within
a defined cellular environment and to control for trans-acting modifiers of gene expression, such as genotype at other loci (Kasowski
et al. 2010; McDaniell et al. 2010; Pastinen 2010; Skelly et al.
2011; Cowper-Sal·lari et al. 2012; Reddy et al. 2012; McVicker
et al. 2013; Buil et al. 2014; Hasin-Brumshtein et al. 2014;
Kukurba et al. 2014; Knowles et al. 2015; Kumasaka et al. 2016).
Here we developed a high-throughput in vitro system to characterize the response to tightly controlled environmental exposures. We then used ASE analysis to identify GxE interactions in
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Figure 1. Overview of gene expression response. (A) Schematic of experimental design and rationale. Our approach uses specific treatment conditions as
tightly controlled proxy for the organism environment and measures molecular phenotypes, such as gene expression, to infer genetic and molecular mechanisms for complex traits. (B) Heatmap of differential gene expression. Shown for each cell type (columns) and treatment (rows) combination are the number of differentially expressed genes (10% FDR and |log2FC| > 0.25). The shade of red indicates the number of differentially expressed genes from an initial
screening step (see Supplemental Texts 5 and 8.1). Cellular environments with a strong response were further sequenced to a higher depth (>58 M reads,
113 M on average), and the number of differentially expressed genes is indicated by the text. Environments marked with an asterisk were chosen to confirm
that treatments with a small response from the shallow sequencing data similarly have a small response when deep sequenced. Colors next to treatment
names represent treatments chosen for deep sequencing. Gray indicates treatments that were not deep sequenced. (C) Global coexpression network inferred using weighted gene correlation network analysis (WGCNA) on 14,535 genes. Each dot represents a gene. Each module is assigned a color based on
the treatment with the highest eigengene t-value. Note that colors representing treatments are consistently used across all the figures.

individual samples at heterozygous sites. We focused on 50 treatments (Supplemental Table S1) in five cell types (250 conditions)
across 15 individuals (three samples per cell type), including paired
vehicle-controls. These treatments represent the cellular counterparts of a range of organismal exposures (Supplemental Table
S1). We broadly grouped the treatments into six categories: steroid
hormones, peptide hormones, metal ions, dietary components,
common drugs, and environmental contaminants. For each
treatment, we used the metabolically active form detected in the
bloodstream at the highest physiological concentration reported
by the Mayo Clinic (http://www.mayomedicallaboratories.com)
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or the CDC (http://www.cdc.gov/biomonitoring/), as available.
Our goal is to identify GxE interactions across these conditions
and characterize their roles in complex traits.

Results
High-throughput characterization of transcriptional responses
Literature reports on transcriptional responses for many treatments across cell types are often contradictory or nonexistent.
To characterize transcriptional responses to 50 environmental
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High-throughput allele-specific expression
perturbations (Supplemental Table S1) in five cell types (250
conditions), we utilized a high-throughput two-step RNA-seq
approach (Supplemental Fig. S2; Moyerbrailean et al. 2015). In
step one, we used shallow RNA-seq (8.2 million reads/sample
on average) (Supplemental Table S2) and DESeq2 (Love et al.
2014) to coarsely characterize global changes in gene expression
(Supplemental Fig. S3; Supplemental Table S3). We considered
only treatment-by-cell-type combinations with more than 80
differentially expressed (DE) genes detected at 10% FDR and
corresponding to |log2FC| > 0.25. We found eight treatments that
induced gene expression changes across all cell types, such as dexamethasone and vitamin A, while other treatments had a celltype–specific effect, such as vitamin B6 in peripheral blood mononuclear cells (PBMCs) (Fig. 1B). Of the 50 treatments, 16 did
not induce significant changes in gene expression in any cell
type. We excluded a few outlier response conditions (see Supplemental Methods 8.2). By using these criteria, we selected 89 conditions (35 treatments across five cell types and three individuals)
corresponding to 297 RNA-seq libraries and resequenced them
to 130 M reads per sample on average (Supplemental Table S4)
in step two.

Treatment-specific gene coexpression network
In step two, we used deep sequencing data and weighted gene correlation network analysis (WGCNA) (Langfelder and Horvath
2008) to infer the global gene coexpression network across all samples and environments (Fig. 1C). This network comprised 87 modules, which grouped genes with similar expression patterns that
may be coregulated in a concerted way. The largest module contained 1456 genes, and the median module size was 42 genes.
We assigned a representative treatment to each module based on
the most significant treatment effect size on gene expression
(Supplemental Fig. S11), and this allowed us to identify clusters
of genes that represent treatment-specific responses. For example,
two modules were each associated with treatment conditions
in opposite directions: module 30 (vitamin D in HUVECs and
PBMCs) and module 22 (caffeine and aspirin in smooth muscle

cells [SMCs]) (Supplemental Figs. S12, S13). These results suggest
that analysis of transcriptional responses to a large number of
treatments in parallel can identify gene regulatory networks
that mediate divergent effects that depend on specific cell type
or treatment conditions.

Analysis of ASE
We used QuASAR (quantitative allele-specific analysis of reads) to
identify genes with evidence of ASE. QuASAR (Harvey et al. 2015)
identifies heterozygous genotypes and uses a beta binomial distribution to infer ASE in RNA-seq data. In the 89 treatment conditions, we identified 11,305 instances of ASE (10% FDR) (Fig. 2),
corresponding to 1455 unique ASE genes. In an individual sample,
0.92% of expressed genes with heterozygous SNPs are ASE genes,
on average.
The ASE analysis was performed on all expressed genes and
was not limited to DE genes as some genes may not change total
expression level. When we consider all ASE genes in our data
set, 92% were also identified with eQTL in the GenotypeTissue Expression (GTEx) Project. Thus, similar to other ASE studies (Buil et al. 2014), we were able to capture genes with regulatory
variants that were previously identified at baseline. Additionally,
many of the genes identified in GTEx with eQTL may have
unknown latent environmental components modulating their
expression.

Analysis of GxE interactions
Next, we characterized GxE interactions on gene expression by
analyzing ASE differences between treatment and control.
Reliably estimating ASE effect sizes required a significant amount
of reads for detecting condition-specific ASE (cASE) (see Fig. 3A;
Supplemental Fig. S15). However, some genes had very low
expression levels in the control condition and high expression
with ASE following treatment, suggesting that expression of these
genes would be induced by a specific treatment. For these cases,
ASE in the control condition cannot be defined accurately. We denoted this phenomenon as induced ASE (iASE) (see Fig. 3B), which

Figure 2. Heatmap of allele-specific expression (ASE). For each individual (row) and treatment (column) we list the number of SNPs displaying ASE (as
determined in QuASAR [quantitative allele-specific analysis of reads] at 10% FDR). The shade of red represents the fraction of ASE SNPs to the number of
heterozygous SNPs tested (% ASE SNPs) in a given sample and condition. The dotted line on the density plot indicates the average % ASE SNPs across all
individual samples and conditions.
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Figure 3. Gene–environment interactions. (A,B) Two types of gene–environment interactions: conditional ASE (A) and induced ASE (B). Treatment conditions are in red and control conditions in blue, with the shade (dark/light) representing the allele (reference/alternate). In this example of cASE, there is an
imbalance of expression between the two alleles in the treatment condition, while the control shows balanced expression. iASE is defined by an imbalance
of expression between the two alleles in the treatment condition and by expression below detectable levels (dotted line) in the control condition. (C) Plot of
all iASE SNPs detected. Each iASE SNP is represented as two points (representing treatment and control expression) connected by a line (representing the
fold-change between conditions). SNPs are plotted based on the expression (TPM [tags per million]) of each allele, with the higher expressed allele in the
treatment on the y-axis and the lower allele on the x-axis. Points are colored by treatment (controls are black and gray), and the dotted lines represent
constant expression levels 0.1, 1, and 10. For ease of display, expression of SNPs <0.01 have been set to 0.01. (D) Scatter plot of the Z-scores in the paired
treatment and control samples for all SNPs tested for cASE. Colored points indicate those displaying cASE: Red is SNPs identified by meta-analysis of subgroup heterogeneity (MeSH) as having cASE in the treatment, blue is SNPs identified by MeSH as having cASE in the control, and green is SNPs identified by
ΔAST (differential allele-specific test) that were not identified by MeSH. (E) QQ-plot of P-values for cASE identified with the ΔAST method for treatment
versus control (green line) and Control 1 versus Control 2 (gray line). (F) Venn diagrams showing the number of cASE SNPs identified by two methods:
MeSH and ΔAST at different empirically estimated FDR thresholds.

indicated cases when the ASE was only observed in genes induced
by the treatment. Studies that only consider baseline eQTL or ASE
may fail to characterize or may mischaracterize genes with iASE
if the relevant environmental stimulus is present as latent exposure. We identified 75 iASE SNPs (10% FDR) corresponding to 60
unique genes (Fig. 3C). The genetic effect in these iASE SNPs is
slightly stronger than that of baseline ASE (Supplemental Fig. S17).
When we can reliably measure ASE in both treatment and
control conditions for the same SNP and individual, we can contrast the amount of ASE between the conditions to determine
cASE. ASE across cell types was never contrasted because the
samples correspond to different individuals. Here we used two approaches to identify cASE (see Fig. 3D): (1) a qualitative “on/off” approach using a meta-analysis framework, and (2) a new quantitative
approach to detect ASE changes even when ASE is present in both
conditions.
For the qualitative analysis of cASE, we used meta-analysis
of subgroup heterogeneity (MeSH) (Wen and Stephens 2014),
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a Bayesian meta-analysis approach that has been previously
used in eQTL studies to contrast effect sizes across conditions
(Maranville et al. 2011) and tissues (Flutre et al. 2013). Here, for
each SNP, individual, and treatment/control experiment pair, we
assume four different mutually exclusive models: (1) no ASE in either condition, (2) ASE in both conditions, (3) ASE in treatment
only, or (4) ASE in control only. Configurations 3 and 4 represent
cASE, while configuration 2 represents shared ASE accommodating for random effects in the genetic effect size. This results in a
stringent test for cASE.
For each of the QuASAR treatment/control measurement
pairs, MeSH calculated a Bayes factor (BF) for each configuration.
We observed that the majority of genes had ASE shared between
the treatment and control conditions (Fig. 3D). We identified
75 SNPs with cASE (difference in the BFtreatment or BFcontrol and
the BFshared > 30) corresponding to 71 unique genes. We observed
a larger proportion of treatment-only cASE compared with controlonly cASE (59 vs. 16) (Figs. 3D, 4). These proportions are consistent
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with observations from eQTL studies contrasting individual treatments and tissues (Maranville et al. 2011; Fairfax et al. 2012; Flutre
et al. 2013; Mangravite et al. 2013).
MeSH detects qualitative interactions and strictly requires
ASE only in one condition analyzed, either treatment or control,
while showing no ASE in the alternate condition. However, these
extreme on/off ASE cases are rare. Other cASE models may exist.
For example, a prior report identified eQTL with genetic effects
in opposite directions in the treatment and control conditions
in stimulated monocytes (Fairfax et al. 2014). Additionally, the
majority of GxE interactions can arise in cases where the genetic
effects differ significantly between treatment and control conditions, but they are nonzero in both conditions.
To capture cASE genes that may have ASE in both conditions
but of a significantly different magnitude, we developed an alternate approach named ΔAST (differential allele-specific test). The
goal was to quantitatively detect GxE interactions. For each heterozygous site, we compared the QuASAR-derived ASE estimates following treatment to those observed in the matched control for
each individual. We calculated a P-value for the difference in ASE
between the two conditions (Fig. 3E).
A key component of our experimental approach is the inclusion of two sets of vehicle controls in each experimental batch,
which empirically estimates the true underlying FDR for identifying cASE, equivalent to permutation-based approaches used in
eQTL studies (see Supplemental Methods 10.3). By use of ΔAST,
we identified 67 cASE SNPs corresponding to an FDR of 10%, 38
of these cASE SNPs were also identified by MeSH. When we relaxed
the FDR threshold (25%), we found a total of 178 cASE SNPs corresponding to 160 genes. Of these genes, 65 were identified with
both methods (Figs. 3D–F, 4).

Features of GxE interactions
When we considered all cASE SNPs, we observed a significant positive correlation between the gene expression log2 (fold change) after treatment and differences in the genetic effect in treatment and
control samples (Fig. 5A). This result could be a consequence of increased power to detect ASE with more highly expressed genes.
However, we observed a negative correlation between gene expression levels and the difference in the genetic effect in the treatment
and the control samples (Fig. 5B). This finding suggests that if a
gene has sufficiently high expression to test for ASE in both conditions, stronger cASE occurs at genes with stronger positive responses to treatment.
To determine if we can validate some of the few previously
known reQTL with cASE, we compiled a list of 134 genes reported
to have GxE effects from prior reQTL and ASE studies. Of these
genes, 83 were heterozygous and could be tested for cASE in
our data (Maranville et al. 2011, 2013; Idaghdour et al. 2012;
Franco et al. 2013; Mangravite et al. 2013; Çalişkan et al. 2015;
Knowles et al. 2015). Sixty-three out of 83 genes were identified
as cASE genes in our analysis (P < 0.05) (Supplemental Table
S13). For example, gene IRF5 has a rhinovirus-reQTL (Çalişkan
et al. 2015) and showed cASE in response to two treatments:
phthalate (P = 0.04) and vitamin B5 (P = 0.04). Additionally,
IRF5 is also linked to autoimmune responsivity through its association to lupus (Sigurdsson et al. 2005; Graham et al. 2006,
2007). Interestingly, phthalates may play a role in lupus etiology
since they induce anti-DNA antibodies (Lim and Ghosh 2005),
while vitamin B5 deficiency is found in lupus patients (Leung
2004).

Figure 4. Forest plot of all cASE SNPs. Each row shows the ASE b̂ for
paired treatment (red) and control (blue) conditions. Defined as in
Figure 2, colored squares indicate the treatment (left) and cell type (right)
in which cASE was identified, along with the gene name and SNP rsID.
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Figure 5. Features of cASE SNPs. (A,B) Scatter plot comparing the absolute difference in ASE b̂ between treatment and control (y-axis) and the average
log2 (expression; A) or log2 (fold change; B) between treatment and control samples for cASE SNPs. The green line indicates the trendline from a linear
model fit on the points. (C,D) Percentage of cASE SNPs identified in each treatment category (C) or treatment (D). For each group, plotted is the percentage
of cASE SNPs identified, relative to the number of SNPs tested for that group. The dotted black line represents the average percentage of cASE SNPs across all
groups. Groups with an asterisk are significantly enriched or depleted (binomial P-value <0.05) relative to the average. The colors in C represent the relative
proportion of cASE SNPs for each treatment in a treatment category.

We next wanted to determine the difference in the number of
cASE SNPs across cellular environments (Fig. 5C,D; Supplemental
Fig. S18). We found that acetylcholine, selenium, and caffeine had
significantly higher numbers of cASE SNPs compared with the
mean number of cASE SNPs per treatment, while acrylamide and
BP-3 had significantly fewer (binomial, P < 0.05). In addition, we
found that environmental contaminants and common chemicals
have a significantly lower proportion of cASE SNPs (P < 0.003).
To assess the extent of GxE interactions on gene regulation
in different cellular environments, we developed an index that
aggregates all cASE tests for each condition and cell type and
determines how much the environment can globally perturb
ASE. To achieve this, we can compare the correlation of the
standardized effect size between treatment and control (as shown
in Fig. 3D) across all SNPs tested for a given cell type and condition.
We denote this genome-wide measurement as environmental
displacement of genetic effect (EDGE) index (for more details,
see Methods). Specifically, the EDGE index is the ratio between
the pair-wise correlation observed between the two control
sets and the correlation observed between the treatment and
control conditions. The EDGE index is one for the control conditions (Supplemental Fig. S19A) and will have higher values for
treatments that can affect ASE for a large number of genes
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(Supplemental Fig. S19B). We find significant differences in the
EDGE index across many treatments (Supplemental Fig. S20). As
expected, we found a high correlation between the proportion
of cASE SNPs and the EDGE index (Spearman ρ = 0.717, P = 3.8 ×
10−6) (Supplemental Fig. S19C).

GxE interactions and complex traits
We then used the GxE interactions we identified in vitro to
characterize putative molecular mechanisms for risk or protective
environmental factors for complex traits (Fig. 6A). We found that
22% of DE genes overlap with those identified in GWAS analyses
(Welter et al. 2014) compared with 4% of nondifferentially expressed genes expressed in our samples (Fig. 6B). This overlap corresponds to a sevenfold enrichment (P < 2.2 × 10−16). These results
suggest that genes responsive to our treatments are more likely involved in organismal traits.
To investigate the role of GxE interactions in complex traits
directly, we analyzed genes containing iASE or cASE. Forty-nine
percent of genes (105 out of 215) that contain either iASE or
cASE were identified by GWAS as associated with various complex
traits; this corresponds to a 3.5-fold enrichment (P < 2.2 × 10−16)
compared with DE genes without iASE or cASE. Importantly, genes
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Figure 6. Integration with GWAS. (A) Hypothetical model detailing the use of GxE interactions to characterize putative molecular mechanisms for risk or
protective environmental factors for complex traits. In the treatment environment, a regulatory region is either active or inactive depending on the haplotype, therefore resulting in different levels of gene expression. In the control environment, the regulatory region is inactive regardless of haplotype. Risk
and protective haplotypes are identified in GWAS. (B) Enrichment analysis of GWAS genes. Reported genes from the GWAS catalog (version 1.0.1) were
compared to different gene sets analyzed in this study: (1) genes that were not differentially expressed in any condition, (2) genes that were differentially
expressed in any condition, (3) genes previously associated with an eQTL in GTEx (eGenes) (The GTEx Consortium 2015), (4) genes containing ASE in any
condition, and (5) genes containing either iASE or cASE. The percentage of genes in these data sets that were found in the GWAS catalog is indicated by a
darker shade. Genes that can be perturbed by our environments are highlighted in purple and indicate a GxE mechanism for the GWAS association. Odds
ratios and enrichment P-values were calculated using a Fisher’s exact test and are shown on the right for each pair of gene categories contrasted.
(C) Genome-wide efficient mixed model association (GEMMA) per SNP heritability estimates relative to the genomic average for cASE (SNPs in genic regions with cASE or iASE), ASE (SNPs in genic regions with ASE), other genic (SNPs in genic regions), and intergenic (SNPs <100 kb from any gene). Only
significant enrichment values are reported, with a darker tone of purple indicating a higher enrichment odds ratio relative to the genome average.
(D) Forest plots of four cASE SNPs in genes associated with a GWAS trait. For each SNP, shown is the ASE b̂ for each treatment in which the SNP was tested.
The 95% CI bars are colored for each treatment as in Figure 2.

with iASE or cASE also have a 1.4-fold increased relevance
for complex traits (P = 0.025) compared with ASE genes and a
3.2-fold enrichment (P < 4.3 × 10−15) compared with genes with
eQTL identified at baseline (eGenes from GTEx). Note that by
design much of our detected ASE may have an environmental
component, but we may lack the power to claim cASE/iASE.

These results suggest that GxE interactions represent an important
mechanism for inter-individual variation in complex traits.
We find similar results when we analyze per SNP heritability
for 18 complex traits using genome-wide efficient mixed model
association (GEMMA) (Zhou and Stephens 2012; Zhou 2016).
Similar to the LD-score regression method that partitions
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heritability estimates across SNPs functional categories (Gusev
et al. 2014), we contrasted SNPs in genes with cASE/iASE, genes
with ASE, genes without ASE, and inter-genic regions. The per
SNP heritability for each of these categories is then compared
with the genome average. A higher value of per SNP heritability
for one of these categories indicates a higher number of causal
SNPs, higher effect sizes, or both in that category. We found that
the per SNP heritability estimate for SNPs in genes with ASE is
11.1 times higher than the genome average for high-density lipoprotein (HDL). For 13 of the 18 traits analyzed, per SNP heritability
estimates for SNPs in genes with cASE, iASE, or ASE were significantly higher than the genome average. For seven of these, the
cASE and iASE category estimates were even higher than any other
partition (Fig. 6C), thus indicating that GxE interaction for these
traits are particularly relevant. The highest values for cASE and
iASE were observed for blood total cholesterol level (TC; 9.7fold), triglicerides (TG; 7.9-fold), and mean corpuscular hemoglobin levels (MCH; 8.6-fold). Overall, these results suggest an important role for GxE interaction in a large number of traits.
When we isolated genes with iASE, we found 28 genes associated with a phenotype in the GWAS catalog (Supplemental
Table S18). Additional investigation into these genes may yield
insights not only on the GxE role in specific traits but also on
the underlying molecular mechanisms. For example, previous reports show that caffeine prevents and treats obesity presumably
through mitotic clonal expansion effects (Li et al. 2015; Kim
et al. 2016; Ohara et al. 2016). Our work suggests that caffeine activates the GIPR pathway, which regulates insulin production.
GIPR is linked to obesity and several obesity-related traits, including body mass index and type 2 diabetes (Saxena et al. 2010;
Speliotes et al. 2010; Fox et al. 2012; Okada et al. 2012; Wen
et al. 2012, 2014; Berndt et al. 2013; Mahajan et al. 2014). We identified a SNP, rs5390, in GIPR that demonstrates iASE following caffeine treatment. Specifically, we found higher GIPR expression and
ASE favoring the rs5390 reference allele following caffeine treatment and low expression in controls. The rs5390 reference allele
is located on the same haplotype as the nonrisk allele for body
mass index in the individual sample used here (Wen et al. 2012,
2014; Okada et al. 2012). These results suggest that caffeine may
reduce obesity through its effect on gene expression and ASE
in GIPR.
Among the genes with cASE, 79 are associated with complex
traits in the GWAS catalog (Supplemental Table S18). Figure 6D
shows four examples of cASE genes associated with complex traits.
These include cASE in SAMM50 in response to copper, in ERAP1
in response to selenium treatment, in GOSR2 following treatment
with mono-n-butyl phthalate, and in LAMP3 in response to selenium. This last example may explain the influence of selenium
on Parkinson’s disease (PD). Previous studies found reduced selenium levels in PD patients (Shahar et al. 2010). In addition, selenium reduces bradykinesia, a well-described symptom of PD, in
rats (Ellwanger et al. 2015), suggesting that higher selenium levels
would be beneficial for PD patients. A GWAS hit for PD (Do et al.
2011; International Parkinson Disease Genomics Consortium
2011) was an eQTL for LAMP3, where the reference/PD-risk allele
led to increased expression of LAMP3 (The GTEx Consortium
2015). In our data, cASE at rs16833703 in LAMP3 preferentially expressed the alternative allele at this SNP, located on the same haplotype as the nonrisk allele at the GWAS SNP. These data suggest
that selenium is beneficial for PD patients through its influence
on allelic expression in LAMP3. Overall, these cASE examples
illustrate genes associated with complex traits, with a plausible
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biological association with the treatment (for details on the other
three genes, see the Supplemental Material).

Discussion
We presented a scalable high-throughput approach to characterize
the effect of environmental and genetic perturbation on gene
expression levels. In this study, we tightly controlled environmental exposure using in vitro treatments in different cell types
and analyzed the transcriptional response for hundreds of conditions that were previously uncharacterized. These results will
be highly valuable to many researchers interested in changes to
specific genes or pathways following various treatments and
cell types. Among the DE genes, we found that 22% have been
associated with complex traits in GWAS. These results strongly
suggest a key environmental component for many complex
traits and should assist the design of future studies. For example,
this resource can help in selecting relevant environmental variables that should be considered in animal models for human
complex traits, in patient studies, and in reanalyzing GWAS data
when the relevant exposure variable was collected as part of the
study.
One of the main advantages of our approach is that it can be
used to detect GxE interaction in a single individual for many
treatments and cell types using ASE analysis. Compared to model
organisms and transgenic models, studying GxE interaction in
humans poses significant challenges. In clinical trials, a limited
number of exposures can be tested, while in large-scale epidemiological studies many exposures convolve together. In this
study, we have analyzed three individuals per cell type in order
to explore a large number of environmental conditions that would
not be practical for a reQTL study design. While some GxE interactions may be detected in a conventional baseline eQTL study, this
would only occur if all or a subset of the samples was exposed to a
relevant environment. However, in eQTL studies, the specific exposure would likely remain uncharacterized as a latent variable
that may be unknown or difficult to model. Though we do not
require many individuals, our approach is limited by the requirement of having two heterozygous variants: at the causal regulatory variant and at the variant for which ASE is measured. A
small fraction of the ASE we detected may actually correspond to
low-frequency variants that are sampled in three individuals, but
the majority will correspond to common variants. The requirement that at least one of the three individuals is a double heterozygote means that we are missing instances of GxE interaction,
especially those at low allele frequencies. Nonetheless, the 215
instances of GxE described here represent a lower bound to the
amount of GxE signal that can be identified by applying our approach to additional treatment panels, cell types, and/or larger
sample sizes.
Our catalog of GxE interactions, and future ones expanding
on the one generated here, will be a necessary resource to thoroughly annotate genes and create a bridge between epidemiological and genome-wide association studies. Here we showed that
49% of genes with GxE interactions are GWAS genes. Although
limited by our false-negative rate, we compiled the most comprehensive list to date of GxE and relevant environmental conditions
that can aide in the interpretation of specific GWAS findings.
We provided some examples of candidate GxE mechanisms for
complex traits and released our results as a browsable web-resource. Mining of our results by other researchers has the potential
to inform new GWAS findings and identify latent variables in
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GWAS that are important risk/protective factors for human complex traits and diseases.
In future research, we anticipate that the approach we developed will potentially aid in precision medicine to tailor medication
exposures using patient cells for improved patient outcomes.
Indeed, when considering potential translation of these findings
to clinical practice, in vitro measurements of ASE for a large panel
of cell types, extracted and derived from single-patient stem cells,
are a promising solution to studying rare disease variants and individualized outcomes of combinatorial interactions of common
genetic variants.

Methods
Cell culture and treatments
Experiments were conducted using the following cell types: lymphoblastoid cell lines (LCLs), PBMCs, human umbilical vein endothelial cells (HUVECs), human SMCs, and melanocytes. LCLs
(GM18507, GM18508, and GM19239) were purchased from
Coriell Cell Repository, cultured, and treated as described previously (Moyerbrailean et al. 2015). PBMCs were derived from whole human blood purchased from Research Blood Components. Blood
specimens were obtained from three individual donors. Primary
HUVECs and SMCs were isolated from human umbilical cord tissue collected shortly following birth. Additionally, cryopreserved
HUVECs (CC-2517-0000315288) and SMCs (CC-2579-7F3794)
were purchased from Lonza. For additional details on HUVEC
and SMC preparation, see Supplemental Methods 1. Primary melanocytes (NHEM) isolated from neonatal foreskin were purchased
from Lonza (CC-2504 lot no. 252410 and 5F0885J) and from
Promocell (C-12400 lot no. 3052103.1). Details on cell culturing
are provided in the Supplemental Methods 2. Supplemental
Table S1 shows the concentrations used for each treatment.
For each treatment panel and cell type, cells derived from
three individuals were treated at the same time on a 96-well plate.
A schematic of the study design is provided in Supplemental
Figure S1.

RNA-seq library preparation and sequencing
We used a two-step approach to gene expression analysis that we
recently developed (Moyerbrailean et al. 2015). A 96-library pooling and shallow sequencing strategy (<10 M reads per library)
(Supplemental Table S2) were used to minimize the amount
of resources used in the first step. For the second step, we repooled
a selection of the initial libraries (Fig. 1B; Supplemental Methods
8.1) to achieve a more uniform allocation of sequencing reads
across samples (130 M reads/sample on average) (Supplemental
Table S4). Pools of 96 samples from step 1 were sequenced
on two lanes of an Illumina HiSeq2500 in fast mode to obtain
50-bp paired-end reads at the University of Chicago and at the
Michigan State University Genomics Cores or were sequenced on
one lane of the Illumina NextSeq500 for 75 cycles of paired-end
in HO mode in the Luca/Pique-Regi laboratory. Step 2 resequencing was performed on the NextSeq500 in the Luca/Pique-Regi
laboratory. The number of reads collected for each sample in
step 1 and step 2 is reported in Supplemental Tables S2 and S4,
respectively.

Sequence alignment and post-processing
RNA-seq data for step 1 was processed as described previously
(Moyerbrailean 2015). For step 2, reads were aligned to the
hg19 human reference genome using STAR (https://github.com/

alexdobin/STAR/releases, version STAR_2.4.0h1) (Dobin et al.
2013) and the Ensembl reference transcriptome (version 75).
Details are provided in Supplemental Methods 7.1. We did not realign the reads to GRCh38 because hg19 is the version of the reference human genome used in the release of the 1000 Genomes
Project that we used for pileup. The 1000 Genomes Project data
were not available in GRCh38 coordinates until October 26,
2016. Realigning the reads should not affect the conclusions as
any problematic region of the genome is excluded from any analysis as detailed in the Supplemental Material. To correct
for potential alignment biases, we used the WASP suite of tools
for allele-specific read mapping (https://github.com/bmvdgeijn/
WASP, downloaded 09/15/15) (Van de Geijn et al. 2015). Note
that we do not use the WASP combined haplotype test (CHT)
as we tested each SNP separately using QuASAR (Harvey et al.
2015). Retained read counts per sample after filtering can be found
in Supplemental Table S4.

Differential gene expression
To identify DE genes, we used the method implemented in the
software DESeq2 (R version 3.2.1, DESeq2 version 1.8.1) (Love
et al. 2014). DE genes were determined as genes with at least one
transcript having a Benjamini-Hochberg controlled FDR (BHFDR) (Benjamini and Hochberg 1995) of 10% and an absolute
log2 (fold-change) >0.25. The same procedure was used for step 1
and step 2. A summary of differential expression for both steps
can be found in Supplemental Tables S3 and S5, and a full set
of differential expression results from step 2 can be found in
Supplemental Table S6.

Network analysis with WGCNA
For network analysis, we used gene expression data normalized as
described in Supplemental Methods 8.4. We combined all the data
across cell types, treatments, and individuals, resulting in a matrix
with 14,527 rows (genes) and 297 columns (samples). We then
used WGCNA (Langfelder and Horvath 2008), version 1.47, implemented in R to build an unsigned network. A soft thresholding
power of six was chosen, and the network was built using the automated block-wise modules pipeline using Pearson correlations, a
signed topological overlap matrix, and a minimum module size of
10. Modules were cut from the network dendrogram with the
dynamic hybrid tree cut method, and the module eigengene was
calculated as the first principal component of each module’s expression matrix. A measure of module membership was calculated
for each gene by correlating the gene’s expression profile with its
module’s eigengene. More details on the network module analysis
are in Supplemental Methods 8.6.

Joint genotyping and ASE inference
To create a core set of SNPs for ASE analysis, we started with all the
SNPs from the phase 3 release of the 1000 Genomes Project
Consortium (www.1000Genomes.org, v5b.20130502, downloaded on 08/24/15) (The 1000 Genomes Project Consortium 2015)
and first removed SNPs with low minor allele frequency (MAF
<5%). We also removed SNPs within the regions of annotated copy number variation and ENCODE blacklisted regions
(Degner et al. 2012), leaving a total of 7,340,521 SNPs in the core
set. Counts of reads covering each allele at selected SNPs (Supplemental Methods 9.1) were obtained by “piling up” aligned reads
for each sample over SNPs using samtools mpileup (Li et al.
2009) and the hg19 human reference genome. All sample pileups
for a given individual across all treatment conditions and the
two treatment plates were processed together (not merged) using

Genome Research
www.genome.org

1635

Downloaded from genome.cshlp.org on January 12, 2017 - Published by Cold Spring Harbor Laboratory Press

Moyerbrailean et al.
the QuASAR package (Harvey et al. 2015) for joint genotyping. ASE
inference was performed for each sample separately. Heterozygous
SNPs with a read coverage greater than 40 were tested for ASE using
QuASAR (Harvey et al. 2015). A summary of the amount of ASE detected in each sample is in Supplemental Figure S10 and Supplemental Table S9. A full list of SNPs tested can be found in
Supplemental Table S10.

Identification of induced ASE
To identify genes with iASE, we selected SNPs that were well covered in the treatment (i.e., more than 40 reads) and had ASE
(10% FDR) but had little to no expression in the matched control.
We used a coverage threshold in the control of 10 × (DC/DT), where
DC and DT represent the sequencing depth of the control and treatment libraries, respectively, in TPM (see Supplemental Methods
9.3). This equates to a ratio of 40 reads to 10 (expression in the control is fourfold lower than the minimum required for a gene to be
considered expressed in the ASE analysis) while accounting for
sequencing depth differences. Finally, we required the SNP-based
log2 (fold change) (Supplemental Methods 9.3) to be >log2(5).

Meta-analysis of subgroup heterogeneity
We used MeSH to model potentially heterogeneous cASE effects
across multiple subgroups contained within the data. The input
to MeSH is a pair of ASE observations derived from QuASAR
summarized by the parameter β measuring the allelic imbalance
and a standard error of the parameter. To look specifically at conditional ASE, a BF for cASE is calculated as BFtreatment − BFshared
(treatment-only cASE) and BFcontrol − BFshared (control-only
cASE). All the cASE BFs are then used to rank and select the observations with strongest evidence for cASE.

ΔAST: a novel method to measure cASE
Differential Z-scores (ZΔ) were calculated from QuASAR β parameters using the following formula. For each SNP,
bT − bC
,
ZD = 
se2T + se2C

(1)

where βT and seT represent the estimates for the ASE parameter
and its standard error for the treatment condition, and βC and
seC represent the corresponding estimates for the control condition. The ZΔ scores were then normalized by the standard deviation across ZΔ scores corresponding to control versus control
(CO1 vs. CO2). Finally, P-values (PΔ) are calculated from the ZΔ
scores as PΔ = 2 × pnorm(−|z|). Under the null, ZΔ are asymptotically normally distributed, and Figure 3C shows that when contrasting the two sets of controls the PΔ-values are almost uniformly
distributed as expected. To further correct for this small deviation,
we used the control versus control P-values to empirically estimate
the FDR (see Supplemental Methods 10.3). The list of significant
cASE SNPs is in Supplemental Table S11.

define this as the EDGE index, which is formally defined as
EDGEs,t =

Pearson(Zs,CO1 , Zs,CO2 )
,
Pearson(Zs,t , Zs,c )

(2)

where Pearson(Zs,t, Zs,c) is the sample Pearson correlation coefficient between treatment t and control c ASE Z-scores across all observed SNPs in cell type s. Equivalently, Pearson(Zs,CO1, Zs,CO2) is
the Pearson correlation coefficient between the two control sets
ASE Z-scores across all observed SNPs in cell type s. The EDGE index values for each cell type and condition can be found in
Supplemental Figure S20 and Supplemental Table S14.

Analysis of heritability enrichment using GEMMA
To run GEMMA (Zhou and Stephens 2012; Zhou 2016), we partitioned SNPs genome wide to create a category file. Each SNP was
assigned to one of the following categories: cASE (genic regions
with conditional ASE) or iASE (genic regions with induced ASE),
ASE (genic regions with ASE), other genic (genic regions that do
not fall into any of the categories above), and intergenic (>100
kb from any gene). We then used GEMMA to compute the SNP
correlations among different categories from a reference panel
(502 individuals of European ancestry from the 1000 Genomes
Project). This was followed by summing the Z 2 statistics from the
GWAS meta-analysis within the categories. Finally, we computed
the proportion of variance and the fold enrichment of heritability
explained by each category. A table of the results can be found in
Supplemental Table S17.

Data access
The RNA sequencing data from this study have been submitted to
the database of Genotypes and Phenotypes (dbGaP, https://www.
ncbi.nlm.nih.gov/gap) under the accession number phs001176.
v1.p1. Additional browsing tools for exploring the data in this project are available at http://genome.grid.wayne.edu/gxebrowser.
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